Topic 1: Foundations in Opioid Use Disorder (OUD) and OUD Treatment

Updated Overview of Substance Use Disorder

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • ASWB ACE: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Apr 24, 2023
  • Expires: Apr 23, 2025
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    (16 Ratings)

The Updated Overview of Substance Use Disorder enduring module is a recording from the live Regularly Scheduled Series dated September 8, 2022. If you claimed credit for this session at the live meeting, you should not claim credit for this module.

Faculty

Michelle R.  Lofwall Michelle R. Lofwall, MD, DFASAM
Professor
Psychiatry and Behavioral Science
Center on Drug and Alcohol Research
University of Kentucky College of Medicine
Bell Alcohol and Addictions Chair and Medical Director
First Bridge Clinic
UK HealthCare
Lexington, Kentucky

Needs Statement

Understanding addiction is essential to successfully addressing it. By understanding the neurological responses to substances and theories of addiction, participants will better be able to treat patients with SUD. Furthermore, substance Use Disorder (SUD) is often looked at as a moral failing and not as a medically treatable chronic illness.

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

  • Identify the spectrum of substance use
  • Describe neurological responses to substances
  • Use accurate terminology

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0922-H1.5-UKHC/Sep22

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 general continuing education credit.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.